Home » COVID-eVax vaccine enters phase I/II study

COVID-eVax vaccine enters phase I/II study

March 4, 2021

No Comments

Article reprints

Source: https://science.bioworld.com/ddn/article.do?id=176807

BioWorld Science

Popular Stories

Free access to BioWorld coronavirus articles
BioWorld
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...
Today's news in brief
BioWorld MedTech
BioWorld MedTech's briefs for July 1.
Novavax vaccine shows its chops
BioWorld
Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
Biomarin outlines pricing strategy for costly hemophilia A gene therapy after backing from European regulators
BioWorld
The first gene therapy to treat severe hemophilia A was among the drugs recommended for European approval by regulators from the EMA’s CHMP at its monthly...
Bluebird’s eli-cel gene therapy for CALD snatches adcom victory from jaws of defeat
BioWorld
The Cellular, Tissue and Gene Therapies Advisory Committee scrutinized Bluebird Bio Inc.’s gene therapy elivaldogene autotemcel (eli-cel) for early active...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe

Upgrade your daily dose of biopharma and medtech news

COVID-eVax vaccine enters phase I/II study